Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
Author(s) -
Francis S. Mah
Publication year - 2011
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s8665
Subject(s) - medicine , itching , antihistamine , allergic conjunctivitis , dermatology , food and drug administration , placebo , anesthesia , allergy , pharmacology , alternative medicine , immunology , pathology
Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This review finds that bepotastine besilate 1.5% solution is a suitable alternative to other agents within the class of H(1)-antihistamines, but there are no clinical trial data to suggest that it holds any specific advantages over other agents.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom